Key facts
- This page summarizes Ramy Farid's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 May 2026, 19:24.
Ramy Farid - 27 May 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- Director
- Issuer ticker
- VIR
- Reported as of
- 27 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 May 2026, 19:24:07 UTC
- Prior SEC filing
- 17 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ramy Farid filed Form 4 for Vir Biotechnology, Inc. (VIR) on 28 May 2026.
Change
- Previous filing in this sequence was filed on 17 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001797707
Primary reporting owner
Farid Ramy
- Relationship
- Director
- Address
- C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
- Signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
- Signature date
- 28 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,000
- Change %
- +33%
- Price
- $0.000000*
- Shares after
- 32,000
- Date
- 27 May 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +16,000
- Change %
- Price
- $0.000000*
- Shares after
- 16,000
- Date
- 27 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,000
- Exercise price
- $9.10
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
Footnote F2
The RSUs will vest in full on May 27, 2027.
Footnote F3
The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.